Liso-Cel Yields Durable Response in R/R B-Cell Lymphomas
Patients treated with liso-cel had a probability of continued response at 2-years of 49.5%.
Addressing Unmet Needs in Hemophilia: Guy Young, MD
The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH study of fitusiran.
CYAD-211 Induces Favorable Safety, Supports Proof of Concept in Patients With Relapsed/Refractory Myeloma
Safety and the recommended dose of CYAD-211 and the lymphodepletion regimen served as the primary end point of the study.
Cilta-Cel Improves Survival in R/R Multiple Myeloma Over Physician Choice of Treatment
Patients treated with cilta-cel had a 76% reduction in the risk of death compared to patients treated with physician's choice of treatment.
Assessing Axi-Cel in R/R LBC Lymphoma in ZUMA-7: Frederick Locke, MD
The vice chair, Blood and Marrow Transplant and Cellular Immunotherapy Program, and co-leader, Immuno-Oncology, Moffitt Cancer Center, discussed the results of the phase 3 ZUMA-7 trial.
Safety Advantages of Tab-Cel Over Other T-Cell Therapies in EBV+ PTLD
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed safety findings from the phase 3 ALLELE study.
Anti-Thrombin siRNA Reduces Bleeding in Severe Hemophilia Without Inhibitors
Annualized bleeding rate, spontaneous bleeding, and joint bleeding rates were all reduced in patients dosed with fitusiran compared to those receiving on-demand treatment.
Anti-Thrombin siRNA Therapeutic Reduces Bleeding in Hemophilia
Over half of patients in the fitusiran arm of the ATLAS-INH study had 0 treated bleeding events.
Optogenetics Device With Gene Therapy is Safe, Efficacious in Retinitis Pigmentosa
Following GS030 optogenetic therapy, the first treated patient was able to locate and count objects on a table and could identify crosswalks in the street.
Beti-Cel Induces Transfusion Independence in Patients With β-thalassemia
The findings, which were simultaneously reported in the New England Journal of Medicine, support beti-cel as a potentially curative, one-time treatment option for these patients.
ADI-001 Highly Effective, Safe for Heavily Pretreated NHL in Preliminary Phase 1 Data
ADI-001 does not require genetic engineering to remove TCRs to avoid GvHD, making them ideal for an off-the-shelf cell therapy.
Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD
The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.
Axi-Cel Superior to SoC in Second-Line Large B-Cell Lymphoma Treatment
Patients treated with the CAR T-cell therapy had an over 4-fold increase in event-free survival.
Gene Edited Cell Therapy Improves Fetal Hemoglobin Expression in Patients With Sickle Cell Disease
All evaluable treated participants experienced a reduction in vaso-occlusive events after treatment with ARU-1801.
Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
Improving Personalized Cell Therapies for Solid Tumors
Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.
Gene Therapy for Diabetic Macular Edema Shows Mixed Efficacy, Safety
Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.
Identifying Future Patients for Tmod Cell Therapy in BASECAMP-1: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
Advantages of T-Cell Immunotherapy Over CAR T-Cells
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.
CRISPR/Cas9-Edited CAR and NK Cell Therapies Show Preclinical Efficacy
CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.
Gene Therapy Optogenetics Combination Efficacious in Retinitis Pigmentosa: José-Alain Sahel, MD
The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.
RGX-314 Gene Therapy Efficacious in Wet AMD: Robert L. Avery, MD
The chief executive officer of California Retina Consultants discussed the positive results of RGX-314 gene therapy in wet AMD.
Assessing Tab-Cel for EBV+ Post-Transplant Lymphoproliferative Disease
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed data from the ALLELE study to be presented at ASH 2021.
OpRegen Shows Durable Efficacy in Dry AMD Geographic Atrophy
The Doheny Image Reading and Research Lab is leading a sub study to analyze OCT images with their proprietary 3D-OCTOR software.
CYNK-101 Demonstrates Anti-Tumor Activity in HNSCC Cells
The NK cell therapy is also being evaluated in a phase 1 study for acute myeloid leukemia.
Dendritic Cell Vaccine Boosts Survival in Glioblastoma
Overall survival was 72% at 12 months but dropped to 54% at 14.6 months.
TIL Therapy LN-145 Elicits Responses in Pretreated mNSCLC
A single administration of LN-145 monotherapy resulted in an overall response rate of 21.4% in patients with immunotherapy pretreated metastatic non–small cell lung cancer.
CAR Macrophages Well-Tolerated, May Reprogram Tumor Microenvironments
The first in-human study of CAR macrophages has dosed 2 participants so far.
Tmod CAR T-Cell Therapy Offers Precise Targeting of Solid Tumors
The BASECAMP-1 study is identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future use of these therapies.
CAR T-Cell Therapy Plus Amplifying Vaccine Shows Initial Safety, Efficacy in Solid Tumors
Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.